New Report Reveals Deep Social Inequities in Counties Hard Hit by Alzheimer’s Disease Among Blacks and Latinos
Report from UsAgainstAlzheimer’s and Urban Institute highlights the importance of addressing the social determinants of health in race to cure and prevent Alzheimer's
Aducanumab is a proposed treatment for early Alzheimer’s disease that is intended to slow the progression of the disease. UsAgainstAlzheimer’s (UsA2) has urged the U.S. Food and Drug Administration to approve aducanumab.
UsAgainstAlzheimer’s Statement on Exciting Development with New Blood Test to Help in Evaluating Patients for Alzheimer’s
UsAgainstAlzheimer’s issued the following statement by George Vradenburg, chairman and co-founder, on the announcement today by C2N Diagnostics of a new, more widely accessible blood test.
Being Patient: National Alzheimer’s Summit: How To Reduce Dementia Risk
At the National Alzheimer’s Summit, experts stressed that it is possible for people to reduce their risk of developing dementia by making certain lifestyle changes.
New Report Reveals Deep Social Inequities in Counties Hard Hit by Alzheimer’s Disease Among Blacks and Latinos
Aducanumab and UsAgainstAlzheimer’s
National Alzheimer's Summit Highlight Reel
UsAgainstAlzheimer’s Statement on Exciting Development with New Blood Test to Help in Evaluating Patients for Alzheimer’s
Being Patient: National Alzheimer’s Summit: How To Reduce Dementia Risk
The 2020 National Alzheimer's Virtual Summit
A Letter from Our Chairman
UsAgainstAlzheimer’s Brain Health Partnership has issued a Call to Action white paper outlining recommendations for building a better system of care to promote brain health and fight back against Alzheimer’s.
November is both National Alzheimer's Disease Awareness Month and National Family Caregivers Month, and it offers an opportunity to recognize the efforts made to end Alzheimer’s and to acknowledge and
COVID-19 and Dementia: Lessons for the Next Pandemic
People with dementia and care partners are among those hardest hit by the COVID-19 pandemic, particularly Black and Latino families. A new UsAgainstAlzheimer’s A-LIST® survey shows ongoing closures and restrictions
COVID-19 and Dementia: Imagining the Future with a Vaccine
With the national conversation focused on when a vaccine for COVID-19 might be approved and available, our recent UsAgainstAlzheimer’s A-LIST® survey asked the Alzheimer’s community about how their lives might
The Pulse of the Community: Coronavirus Impacts on Alzheimer's Community
The A-LIST transforms the stories of more than 7,500 people living with Alzheimer’s or other dementias into evidence-based insights by providing unique, rapid-response, self-reported data through virtual surveys on what matters most on a wide range of Alzheimer’s-related topics. The A-LIST offers a powerful and validating voice for those living with Alzheimer’s and those caring for them, and a pathway to help expand treatments and accelerate toward a cure.
